[ET Net News Agency, 28 February 2024] HSBC Global Research raised the target price for
Sh Pharma (02607) to HKD18.9 from HKD12.9 and upgraded the rating to "buy" from "hold".
The research house said it raises revenue estimates in 2024-25e by 3.8% on average to
reflect the pipeline delivery. (RC)